ETF·NASDAQ
iShares Biotechnology ETF (IBB)
- Net assets
- $11.20B
- Expense ratio
- 0.44%
- Yield
- 0.16%
- 52-week range
- $153.25 $217.12
The short version
Where IBB stands today, in four lines, and what CleaRank Financial AI makes of it.
IBB at a glance
iShares Biotechnology ETF (IBB): Buy, 68/100 on CleaRank's AI score.
- Trend Mixed: the price is above its 200-day but below its 50-day moving average ($182.74 and $206.68).
- Fund Expense ratio 0.44%, $11.2B in net assets, +46.1% total return over 1 year.
Figures as of October 17, 2026.
CleaRank Financial AI
CleaRank rates iShares Biotechnology ETF (IBB) a Buy with a model score of 68/100.
Trend contributes the most to that score: the price is 10.54% above its 200-day average and the 50-day average sits 13.10% above the 200-day. The MACD line is negative, which is the largest drag on the score. The 50-day average is $206.68 and the 200-day is $182.74, and the price rose 31.66% over the last year.
Only on CleaRank
Figures we compute ourselves from IBB's own price history. Tap one to see it in context.
Price and trading
The chart, today's range and how far the price has moved over each period.
Trend checks
3/4Price above its 50-day average ›
The price of $201.99 is 2.3% below the 50-day simple moving average of $206.68.Price above its 200-day average ›
The price is 10.5% above the 200-day simple moving average of $182.74.50-day average above the 200-day ›
The 50-day average ($206.68) is 13.1% above the 200-day average ($182.74), the arrangement of a rising longer-term trend.In the upper half of its 52-week range ›
The price sits at 76% of its 52-week range, between $153.25 and $217.12.
IBB share price
Pick a period: each tab shows how far IBB has moved over it, to the last close.
Today's trading
Where IBB sits inside today's range and its 52-week range.
Fund facts and valuation
What the fund holds, what it costs and how it is valued.
Fund checks
3/5Expense ratio at or below 0.20% ›
The fund charges 0.44% a year, $44.00 on a $10,000 holding.Over $1B in net assets ›
Net assets total $11.2B.No sector above 35% of the fund ›
The largest sector, Healthcare, makes up 100.0% of the fund.Pays a distribution ›
The distribution yield is 0.16%.Positive return over one year ›
The fund family reports a one-year total return of 46.08%.
IBB Fund Facts
iShares Biotechnology ETF is an exchange-traded fund that provides broad exposure to U.S.-listed biotechnology companies. The fund is designed to track a biotechnology-focused index and typically holds a diversified basket of large, mid, and smaller biotechnology names, along with select life sciences tools and services companies that support drug discovery and research. Its portfolio includes firms involved in areas such as therapeutics, genetic medicine, diagnostics, and advanced research platforms.
Sector weights
Trailing total returns
| Period | IBB |
|---|---|
| YTD | 24.80% |
| 1 month | 0.67% |
| 3 months | 10.71% |
| 1 year | 46.08% |
| 3 years | 20.12% |
| 5 years | 5.69% |
| 10 years | 8.37% |
As of Oct 17, 2026, IBB has an expense ratio of 0.44%, $11.20B in net assets and a distribution yield of 0.16%.
Fund reference data as of Oct 17, 2026. Expense ratio and net assets are reported by the fund; returns are total returns and can differ from price change.
Key statistics
The headline figures for IBB.
What the numbers say
CleaRank Financial AI's reading of IBB's holdings, performance and risks.
IBB, the iShares Biotechnology ETF, rests on a single pillar: Healthcare makes up 100.0% of the fund. That concentration means IBB moves largely in step with that one sector. The fund is a Health offering from iShares and was launched on February 5, 2001.
Costs run at 0.44% a year, which works out to $44.00 on a $10,000 holding. The fund has $11.2B in net assets. Its distribution yield is 0.16%, and portfolio turnover stands at 27%.
Normal swings for IBB run at about 1.54% a day. Concentration matters here: Healthcare makes up 100.0% of the fund, so a setback in that sector would weigh on the whole.
AI analysis and technicals
CleaRank's score and reasoning, the indicators behind it, and what the price moves with.
Momentum checks
1/3RSI not overbought or oversold ›
The 14-day RSI is 45.8, in neutral territory.RSI above 50 ›
An RSI of 45.8 is below the 50 midpoint, so sellers have had the upper hand over the last 14 days.MACD line above zero ›
The MACD line is negative, so the 12-day average is below the 26-day average.
CleaRank AI analysis of IBB
The score, the reasoning behind it, and what could move the price next.
IBB, the iShares Biotechnology ETF, is caught between its two moving averages. Its price of $201.99 stands 10.54% above the 200-day average of $182.74, yet it sits 2.27% below the 50-day average of $206.68. The price is 6.97% below the 52-week high of $217.12, which leaves it at 76% of its 52-week range. The 50-day average is also 13.10% above the 200-day average.
A recent pullback sits inside a stronger longer record: the price fell 0.20% over the past month, rose 6.44% over the past three months and rose 31.66% over the past year. On momentum, the 14-day RSI reads 45.8, in the neutral zone, with the MACD line negative.
- Two levels deserve the closest watch: the 20-day EMA, which sits at $205.12 above the price, and the 200-day SMA, which sits at $182.74 below it.
- A 14-day RSI of 45.8 is neutral, and the MACD line is negative. Readings above 70 or below 30 would signal stretched momentum.
- Costs compound: at 0.44% a year, IBB charges $44.00 on every $10,000 invested.
IBB sits in a mixed trend. The price is above its 200-day average of $182.74 but under its 50-day average of $206.68. Should the price close above the 50-day, both signals would point up; a close below the 200-day would push both down. For now, the price is wedged between the 200-day SMA ($182.74) below and the 20-day EMA ($205.12) above.
Technical indicators
Momentum and trend for IBB, from its daily closes.
As of October 17, 2026, with IBB at $201.99, its 14-day RSI is 45.8 (neutral territory), its 50-day simple moving average is $206.68 and its 200-day is $182.74.
Calculated by CleaRank on daily closes as of October 17, 2026: Wilder's 14-day RSI, 50- and 200-day simple moving averages, MACD line (12, 26).
What IBB moves with
Correlation of daily returns over one year: +1 moves in step, 0 has no link, -1 moves the opposite way.
As of October 17, 2026, IBB's 1-year correlation of daily returns is +0.57 with S&P 500 (SPY), +0.49 with Nasdaq 100 (QQQ), +0.28 with Bitcoin (BTC) and +0.21 with gold (XAU).
A trade plan, if you want one
Entry, stop and target levels from the moving averages and recent volatility. Educational, not advice.
IBB trade plan
Entry, stop and target levels, sized to your account. Change the bias or the risk and every level updates.
Long entry pick an entry style
Risk management
Profit targets (Based on Conservative Entry)
These levels come from IBB's moving averages and recent volatility, not from a forecast. Educational levels, not financial advice; the full disclaimer is at the foot of the page.
Risk profile
How much IBB tends to move, against the market and on its own.
The long record
IBB's worst falls and recoveries, what $10,000 became, and which months have been kind to it.
Track record checks
3/4Average daily move under 2% ›
The price has moved 1.54% on an average day (30-day standard deviation of daily returns).Recovered from its worst fall ›
The worst fall was 38.2%, from August 2021 to June 2022, regained by January 2026.Most 1-year holds ended higher ›
67% of 1-year holding periods in the last 10 years ended with a gain.Beat the S&P 500 since the chart begins ›
$10,000 invested in October 2016 is now worth $23,355, against $42,055 in the S&P 500 (SPY).
IBB Drawdowns & Recovery
As of October 17, 2026, IBB's worst peak-to-trough fall over the last 10 years with dividends reinvested was -38.2% (August 2021 to June 2022); it regained that peak by January 2026, 43 months after the low, and 67% of 1-year holding periods ended with a gain.
From weekly closing values with dividends reinvested. A drawdown is the fall from the highest value reached so far to a later low.
Growth of $10,000
What $10,000 put into IBB in October 2016 is worth now, against the same amount in the S&P 500.
Against the market: IBB trailed the S&P 500 over this period: $23,355 against $42,055.
A $10,000 investment in IBB in October 2016 would be worth about $23,355 today with dividends reinvested, compared with about $42,055 for the same investment in the S&P 500 benchmark (also with dividends reinvested).
Seasonal patterns
Which calendar months have been kind to IBB, and which have not.
Strongest month, June: an average of +4.28%, up in 9 of 10 years.
Weakest month, March: an average of -3.16%, up in 2 of 10 years.
This month, October: has averaged +0.01%, up in 3 of 9 years. Past seasonality does not repeat on schedule.
Over the last 10 years, IBB's strongest calendar month has been June (average +4.28%, up in 9 of 10 years) and its weakest March (average -3.16%, up in 2 of 10 years).
Average return for each calendar month over the last 10 years, from weekly closing prices with dividends included.
Long-term scenarios
Thousands of simulated paths from the price history. A range of outcomes, not a forecast.
Monte Carlo projection
Thousands of simulated paths for $10,000 in IBB, from its own past volatility. The shaded area holds 80% of them.
CleaRank's 10-year Monte Carlo simulation projects that a $10,000 investment in IBB today could grow to about $20,098 by 2036 in the base case, with a 90th-percentile outcome near $51,519 and a 10th-percentile outcome around $7,841. The simulation models price only; at today's 0.16% yield, dividends would add to these figures. Projections are statistical simulations, not guarantees.
IBB 2030 Scenarios (Monte Carlo)
The same simulation in share prices, year by year.
CleaRank's simulation projects a price near $267 for IBB by 2030 in the base case, from $202 today (1.3x over 4 years). The 10th-percentile path ends near $147. These are outcomes of a Monte Carlo simulation run on IBB's historical return distribution, not price targets, and they assume no dividends are reinvested.
| Year | 10th percentile | Base case | 90th percentile | range base today |
|---|---|---|---|---|
| 2027 | $161 | $217 | $292 | |
| 2028 | $152 | $232 | $354 | |
| 2029 | $149 | $249 | $417 | |
| 2030 | $147 | $267 | $484 | |
| 2031 | $147 | $286 | $557 |
Method: a lognormal simulation of IBB's own volatility and capped historical trend, re-run daily; base case is the median path, the outer columns the 10th and 90th percentiles.
Questions people ask
Answered from the figures on this page, as of October 17, 2026.